Ascendis Pharma A (ASND) Gross Profit (2021 - 2026)

Ascendis Pharma A has disclosed Gross Profit across 6 years of filings, most recently posting $268.2 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $268.2 million, up 205.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $895.8 million (up 166.39% YoY), and the FY2025 annual result was $727.8 million, up 89.18% from the prior year.
• Gross Profit came in at $268.2 million for Q1 2026 at Ascendis Pharma A, up from $260.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $268.2 million in Q1 2026 to a low of $2.9 million in Q1 2022.
• The 5-year median for Gross Profit is $51.2 million (2024), against an average of $94.6 million.
• Across the five-year window, Gross Profit soared 1054.34% in 2022 and dropped 29.6% in 2024, its largest moves.
• Ascendis Pharma A's Gross Profit stood at $18.1 million in 2022, then jumped by 601.2% to $127.2 million in 2023, then jumped by 34.3% to $170.9 million in 2024, then surged by 52.54% to $260.6 million in 2025, then climbed by 2.9% to $268.2 million in 2026.
• The last three Gross Profit figures came in at $268.2 million (Q1 2026), $260.6 million (Q4 2025), and $223.6 million (Q3 2025), per Business Quant data.